Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

Regeneron Pharmaceuticals ... Company Limited (“Hansoh”) to acquire exclusive clinical development and commercial rights outside of China for HS-20094 (a dual GLP-1/GIP receptor agonist ...

(RTTNews) - Regeneron Pharmaceuticals (REGN) announced an in-licensing agreement with Hansoh Pharmaceuticals to acquire clinical ... provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist.

Credit: lev radin/Shutterstock. Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS-20094. The agreement will involve the ...

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China Phase 2 data suggest potentially similar ...

Additionally, Regeneron has entered into a licensing agreement with Hansoh Pharmaceuticals for the obesity drug candidate HS-20094 ... $1.93 billion. This acquisition is expected to enhance ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Additionally, Regeneron has entered into a licensing agreement with Hansoh Pharmaceuticals for the obesity drug candidate HS-20094, with an upfront payment of $80 million and potential future ...